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A B S T R A C T
The current work envisages synthesis of an ester prodrug of flurbiprofen whereby its car-
boxylic group was condensed with a skeletal muscle relaxant methocarbamol, with the aim
of synergistic activity of two drugs, avoid flurbiprofen mediated gastro-intestinal damage
and minimize the ulceration tendency of flurbiprofen. The synthesized prodrug was char-
acterized and confirmed by physicochemical and spectroscopic studies. Solubility and partition
coefficient studies indicated an increased lipophilicity and thus better suitability for oral
administration than the parent drugs and the protein binding studies revealed a low protein
binding capacity of the mutual prodrug. Subsequently, in-vitro hydrolysis was studied in dif-
ferent pH, simulated gastric fluid, simulated intestinal fluid and plasma and quantitative
evaluation was performed by high performance liquid chromatography. It was found that
the prodrug remained unhydrolyzed in the stomach after absorption however, underwent
rapid cleavage by the esterases in blood to give the parent drug. Furthermore, the mutual
ester prodrug was evaluated for its anti-inflammatory, analgesic, skeletal muscle relax-
ation, ulcerogenic and total acid content activity and was found to possess comparable activity
with that of the parent drugs. Microscopic structures of the stomach tissues revealed sig-
nificant reduction in gastric ulcer formation of mice gastric mucosa as compared to parent
carboxylic acid drug.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
NSAIDs are a vast group of medications that are highly praised
nowadays for their triple action: analgesic, antipyretic and anti-
inflammatory activities. The nonsteroidal anti-inflammatory
drugs are the most widely prescribed and used drugs for
rheumatologic as well as nonrheumatologic conditions, which
include acute and chronic pain [1], biliary, ureteric colic [2], dys-
menorrhea [3], fever, and other applications [4]. In other words,
NSAIDs help to relieve pain, lower high body temperature or
fever and reduce inflammation.These are more prescribed than
* Corresponding author. Department of Quality Assurance, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, Shivaji Univer-
sity, Kolhapur 416013, Maharashtra, India. Tel.: +91 231 2637286; fax: +91 231 2638833.
E-mail address: neela.bhatia20@gmail.com (N. Bhatia).
Peer review under responsibility of Shenyang Pharmaceutical University.
http://dx.doi.org/10.1016/j.ajps.2015.10.031
1818-0876/© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 4 4 9 – 4 5 8
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
HOSTED BY
ScienceDirect
opioids because of no narcotic effect and dependence risk.
NSAIDs block the production of substances in the body called
prostaglandins that play a role in pain, inflammation, fever,
and muscle cramps and aches. At low doses, NSAIDs work es-
sentially as pain relievers while at higher doses they can actually
reduce the body’s inflammatory response to tissue damage as
well as relieve pain.
Almost all NSAIDs on long-term treatment inhibit the
enzyme cyclo-oxygenase (COX) and production of prostaglan-
dins [5]. Continuous intake of NSAIDs results in irritation of
the gastric mucosa and enhances ulceration by blocking pro-
tective action of the prostaglandins on gastric mucosa, causing
ulcer formation not only in the stomach but also in the lower
part of the esophagus and also in the duodenum. In general,
the properties of NSAIDs that contribute to ulcerogenesis can
be divided into two categories: topical irritancy and the sup-
pression of prostaglandin synthase activity. In addition, NSAIDs
tend to damage the mucosa due to the presence of acid in the
stomach and in the duodenum and in some cases due to the
presence of Helicobacter pylori (H. pylori) [6]. The gastrointesti-
nal side effects of NSAIDs are generally attributed to direct and/
or indirect mechanisms.The direct contact effect results usually
from a local irritation produced by the acidic group of the
NSAIDs and local inhibition of prostaglandin synthesis in the
GI tract. The indirect mechanism is due to a generalized sys-
tematic action occurring after prior absorption.
Prodrugs, the pharmacologically inactive derivatives of active
drugs, are designed to maximize the amount of active drug that
reaches its site of action, through manipulation of the physi-
cochemical, biopharmaceutical or pharmacokinetic properties
of the drug. Prodrug synthesis is one of the approaches to
modify chemical and physical parameters of parent drugs to
overcome their limitations [7]. At the same time, biotransfor-
mation of a prodrug to its parent compound at its target site
of activity may be used to achieve rate-controlled and time-
controlled drug delivery of the actives [8].The prodrug approach
has the ability to keep promising new drug candidates alive
through development and to improve the safety and efficacy
of existing drug products. It is a very fruitful area of research
and its introduction in human therapy has given successful
results in improving the clinical and therapeutic effective-
ness of drugs with undesirable side-effects [9–11].
The aim of designing a mutual prodrug is to overcome limi-
tations of a parent drug that would otherwise hinder its clinical
use. Gastric mucosal injury produced by NSAIDs is generally
aggravated by the local irritation caused by acidic group of
NSAIDs [12,13].The temporary masking of this group may offer
relief to the patient suffering from GI irritation; hence, prodrug
approach is the most suitable technique for this purpose. The
current work deals with a potent anti-inflammatory drug as-
sociated with GI irritation, flurbiprofen, which was selected as
a model drug for carboxylic acid derivatization. Another drug,
methocarbamol, is also clinically prescribed for painful spasms
associated in GI disorders as skeletal muscle relaxant [14]. The
rationale of this work was to couple flurbiprofen with
methocarbamol to achieve reduced GI irritation and related side
effects along with a synergistic effect of both actives. Gener-
ally, these two drugs are prescribed in combination; however,
this combination often reveals the side effects associated with
each other. Coupling of both compounds as a hybrid drug or
through a spacer known as a mutual prodrug can result in a
potent anti-inflammatory compound with reduction of the main
adverse local effects related to the activity of the NSAID and
skeletal muscle relaxant.
2. Materials and methods
2.1. Materials
NSAID flurbiprofen and skeletal muscle relaxant methocarbamol
were kindly provided by Sun Pharma, Mumbai and Synthochem
Pvt. Ltd., Hyderabad.The other reagents and solvents used were
of analytical/spectroscopic/HPLC grade as needed. The reac-
tions were monitored by TLC on precoated silica G plates using
iodine vapor as detecting agent. Melting points were recorded
using capillary tube method. IR spectra were obtained by a
Shimadzu IR spectrophotometer using KBr pellets. 1H NMR
spectra were recorded using DMSO on a Bruker-300 AVANCE in-
strument. Chemical shifts are expressed as δ (ppm). HPLC
analysis, i.e. in-vitro hydrolysis studies, were carried out using
a Jasco HPLC system using mobile phase acetonitrile:water (80:20)
and detection wavelength 228 nm with flow rate 1 ml/min. The
protocol for the animal experiments performed was approved
by the IAEC (Institutional Animal Ethics Committee) as regis-
tered under the Committee for the Purpose of Control and
Supervision of Experiments on Animals (Reg.No.988/C/06/
CPCSEA); approval number (BVCPK/CPSCEA/IAEC/01/08).Activities
were carried out at the Department of Pharmacology, Bharati
Vidyapeeth College of Pharmacy, Kolhapur.
2.2. Synthesis of prodrug
The reaction for synthesis of prodrugs involved two steps. The
first step consisted of acid chloride formation and the second
step gives formation of mutual prodrug (Fig. 1). Acid chloride
formation is initiated by reacting flurbiprofen with thionyl chlo-
ride. The acid chloride of flurbiprofen was synthesized by
reacting with excess thionyl chloride and refluxed for 30 min
in RBF. After completion of the reaction, the mixture was cooled
to room temperature and the excess of the thionyl chloride was
removed from the reaction mixture. The product (acid halide
derivative of flurbiprofen) was collected and then washed with
water.
In the second step, the acid chloride of flurbiprofen was
treated with the other drug methocarbamol to form the mutual
prodrug. A three-necked flask with a sealed stirrer was fitted
with a reflux condenser and a dropping funnel. 0.77 mol of
methocarbamol, 0.84 mol of pure dimethyl aniline and 100 ml
of anhydrous ether was placed in the flask. The stirrer was set
in motion and the mixture was heated to gentle reflux on a water
bath. 0.79 mol of redistilled acid chloride of flurbiprofen was run
at such a rate that moderate refluxing continued after heating
was removed. When two-third of the acid chloride was intro-
duced, the dimethyl aniline hydrochloride commenced to
crystallize and then the mixture was refluxed vigorously. Sub-
sequently, it was cooled on an ice bath and after the refluxing
ceased, the remainder of the acid chloride was added. The
mixture was then heated on a water bath for 1 h. It was cooled
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to room temperature, 100 ml of water was added and the stir-
ring was continued until all the precipitated solid has dissolved.
Diethyl ether was added to the cooled mixture. The ether layer
was separated and ether was removed from it by evaporation.
The product was collected and washed with hot water then re-
crystallized by ethyl acetate.The yield was found to be 66% [15].
The synthesized compounds were subjected to TLC to check
their purity. A solvent system ethanol:water (70:30) was used
and iodine vapor was used as detecting agent. Melting point of
parent drugs and synthesized flurbiprofen and methocarbamol
(FLP-MET) prodrug was determined by capillary tube method.
The structures of the synthesized compounds were estab-
lished by their spectral (IR, NMR and mass spectral) analysis.
2.3. Determination of solubility and partition coefficient
Solubility of synthesized prodrug was determined in water,
methanol, ethanol, chloroform, acetone and ether. Synthe-
sized compounds were added to solvent (5 ml) in a vial that was
tightly closed and subjected in a rotating shaker overnight at
60 rpm at room temperature, ensuring that equilibrium was es-
tablished. The solutions were filtered through Whatman filter
paper and filtrate was taken in an evaporating dish.The solvent
was evaporated off and the weight of the residue was deter-
mined [16].
Partition co-efficient of the synthesized prodrug was deter-
mined in three systems viz. octanol:water, octanol:water (pH 1.2)
and octanol:phosphate buffer (pH 7.4) at 25 °C temperature. Syn-
thesized compound (10 mg) was added to 10 ml of organic phase
and 10 ml of aqueous phase was added to it. The mixture was
shaken for 1 h and left for 2 h at 25 °C.The two layers were sepa-
rated out using a separating funnel. Prodrug concentration in
aqueous phase, in hydrochloric acid buffer (pH 1.2) and phos-
phate buffer (pH 7.4), was determined from calibration curve
plotted for the prodrug in the respective solvents [16,17]. The
partition coefficient was calculated by Equation (1).
Partition coefficient
Concentration of drug in organic pha
=
se
Concentration of drug in aqueous phase
(1)
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Fig. 1 – Scheme for synthesis of FLP-MET prodrug: (A) Acid chloride formation; (B) Synthesis of mutual prodrug from
flurbiprofen and methocarbamol.
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2.4. Protein binding studies
Stock solution of FLP, MET, FLP-MET prodrug each of concen-
tration 10 mg/ml was prepared in phosphate buffer saline (PBS,
pH 7.4). These solutions (100 ml) were taken in three sepa-
rate beakers. Cellophane membrane with molecular weight cut
off in the range 10,000–12,000 Dalton were first washed with
distilled water and then with buffer solution (pH 7.4) and tied
at one end of the dialysis tube. Egg albumin (6%) was then filled
into the dialysis tube through the other end and was dipped
into the drug solutions and covered. The whole assembly was
placed on a magnetic stirrer and switched at low rpm.The tem-
perature was maintained at 37 ± 0.5 °C. After every hour, 1 ml
of PBS from three different beakers containing drug solu-
tions were withdrawn and immediately replaced with fresh PBS.
Withdrawn samples were diluted further with 1 ml PBS and
concentration of those solutions was estimated using spec-
trophotometer at 248 nm for FLP, 221 nm for MET and 247 nm
for FLP-MET prodrug, respectively [18].
2.5. Hydrolysis study of mutual prodrug
Human plasma was procured from local blood bank to which
1 ml of acetonitrile was added and centrifuged for 15 min at
5000 rpm for separation of proteins.The supernatant was passed
through the 45 mu syringe filter and used for hydrolysis study.
The amount of drug that remained was determined by high
performance liquid chromatographic analysis. HPLC analysis
was done using HIQ Sil C-18 column (250 mm × 4.6 mm, 5 mu),
using the mobile phase acetonitrile:water (80:20) and detec-
tion wavelength 228 nm with flow rate of 1 ml/min.
Stock solution of prodrug was prepared in methanol. Hy-
drolysis of mutual prodrug was studied under physiological
conditions at different pH 3.0, 4.0, 5.0 and 7.4 in 0.05 M phos-
phate buffer at 37 °C. Stock solution (10 ml) was added to 90 ml
of preheated buffer solution in screw capped test tubes.To carry
out hydrolysis study in plasma, 2 ml of phosphate buffer (pH 7.4)
was added to 8 ml of collected plasma at 37 °C. The reaction
was initiated by adding 1 ml of the stock solution of prodrug
to 9 ml of preheated diluted plasma in a water bath at 37 °C.
To study the hydrolysis of synthesized prodrug in simulated
gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF,
pH 6.5) as per USP, the reaction was initiated by adding 1 ml
of stock solution of prodrug to 9 ml of preheated SGF and SIF,
which were maintained at 37 °C. The reaction was done in a
water bath at 37 °C, and at appropriate intervals, 1 ml sample
was withdrawn and diluted with 9 ml of mobile phase and in-
jected for chromatographic analysis [19,20].
After carrying out the hydrolysis study, the percent remain-
ing concentration of the prodrug was calculated and then the
rate constant (k) and half life (t1/2) values of the prodrug for
different pH and plasma were calculated as in Equation (2).
k
t
a
a x
t
k
=
−( ) =
2 303 0 693
10 1 2
.
log
.
(2)
where k = specific reaction rate constant; t = time for which hy-
drolysis is carried out; a = Initial concentration of prodrug;
a − x = concentration of prodrug remaining at time t; t1/
2 = half life.
2.6. Anti-inflammatory activity
The anti-inflammatory activity of synthesized prodrug was
evaluated using carrageenan-induced paw edema method on
mice [11].Three albino mice with a body weight of 20–30 g were
used for each test and control group. The animals were starved
overnight. Before injection of the test compounds, the volume
of the paw was measured plethysmographically by Vernier
caliper. Animals were pretreated orally with drug solutions in
the form of suspension prepared in 5% carboxy methyl cellu-
lose.The control group received the same volume of the vehicle.
Edema was induced after 30 min by sub-planter injection of
0.05 ml of a 1% solution of carrageenan solution in the ani-
mal’s left hind paw. The dose of flurbiprofen (standard)
100 mg/kg and dose of FLP-MET prodrug (test) 194 mg/kg was
administered. The increase in paw volume was determined at
1, 2, 3, 4, and 5 h after injection of the carrageenan; flurbiprofen
was used as standard for the test. The percent swelling inhi-
bition was calculated using Equation (3).
Inhibition % =
Vt Vo Control Vt Vo Treated
Vt Vo Control
( ) −( ) − −( )
−( ) 100 (3)
where Vt and Vo relate to the average volume in the hind paw
of the mice before any treatment and after anti-inflammatory
agent treatment, respectively. Results were expressed as
mean ± SD.
2.7. Analgesic activity
Analgesic evaluation of the drugs was made using a previ-
ously reported method [21]. Mice of either sex with weight
20–25 g were used. Acetic acid 0.01 ml in a concentration of 0.6%
is injected intra-peritoneally. Groups of 3 animals were used
for control and treated mice. The drug or the standard was ad-
ministered intra-peritoneally to the test animals at various
pretreatment times prior to acetic acid administration.The dose
of flurbiprofen (standard) 100 mg/kg and dose of FLP-MET
prodrug (test) 194 mg/kg was administered. The mice were in-
dividually subjected into glass beakers and 5 min were allowed
to elapse. The mice were then observed for a period of 10 min
and the number of writhes was recorded for each animal. For
scoring purpose, a writhe was indicated by stretching of the
abdomen with simultaneous stretching of at least one hind
limb. Percent inhibition was computed by Equation (4).
Protection
Number of writhings in test
Number of wri
%( ) = −100
things in control
⎛
⎝⎜
⎞
⎠⎟ × 100
(4)
2.8. Skeletal muscle relaxant activity
The apparatus consisted of horizontal metal rod coated with
rubber with 3 cm in diameter and attached to a motor with
the speed adjusted to 2 rpm. The rod was 75 cm in length and
was divided into 3 sections by plastic discs, thereby allowing
the simultaneous testing of 3 mice. The rod was about 50 cm
above the table top to discourage the animal from jumping off
the roller. Mice with weight 20–30 g underwent a pretest on
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the apparatus. Only those mice that demonstrated their ability
to remain on the revolving rod for at least 1 min were se-
lected for the test. The test compounds were administered for
30 min after intraperitoneal administration or 60 min after oral
administration and the mice were placed for 1 min on the ro-
tating rod. The dose of methocarbamol (standard) was 200 mg/
kg and dose of FLP-MET prodrug (test) was 388 mg/kg. The rota
rod apparatus was adjusted at a speed of 25 rpm.The time taken
by each animal to fall from the rotating rod was taken as a re-
sponse (fall off time). An untreated mouse generally falls off
within 3–5 min. Percent decrease in time was calculated using
Equation (5) [22].
% Decrease in time to fall
Va
Vb
= −
⎛
⎝⎜
⎞
⎠⎟ ×100 100 (5)
where Va = time taken by the animal to fall from the rotating
rod after treatment with drug and Vb = time taken by the animal
to fall from the rotating rod before treatment with drug.
2.9. Ulcerogenic activity
Ulcerogenic activity was performed as per the protocol men-
tioned in literature [23]. Groups of 3 Swiss albino mice with a
weight 20–30 g were used for the control, standard and test com-
pounds. The mice were fasted overnight with access to water.
The doses were chosen considering the activity in the anti-
inflammatory tests in mice. The test compound (FLP-MET) was
suspended in 0.1% methyl cellulose and given orally as 1 ml
suspension to the first group. Similarly, the second group was
given equivalent dose of flurbiprofen that serves as standard
and the third group received equivalent amount of vehicle (CMC)
that serves as control. The dose of flurbiprofen (standard)
100 mg/kg and dose of FLP-MET prodrug (test) 194 mg/kg was
administered.The dosing was continued for two days. Food was
withdrawn from all groups for 24 h after the last dose.The mice
were then sacrificed 8 h post last dosing and their stomach were
removed and placed on saline-soaked filter paper until in-
spection. A longitudinal incision along the greater curvature
was made with fine scissors.The gastric contents were emptied
for determination of total acid content. The stomach was in-
verted and the presence or absence of gastric irritation was
determined. In the presence of single or multiple lesions (ero-
sions, ulcers or perforation) was considered to be positive. The
number of ulcers and hyperemia was noted. Ulcer index was
calculated by Equation (6).
Ulcer Index =
10
x
(6)
where x = total mucosal area/total ulcer area.
2.10. Total acid content
To determine the total acid content, the gastric contents were
centrifuged at 1000 rpm for 10 min. 0.1 ml of supernatant was
diluted with 9 ml of distilled water and titrated against 0.01
N sodium hydroxide using 2 drops of phenolphthalein as in-
dicator until permanent pink color was observed. The volume
of NaOH required to give total acidity was noted.
Acidity (mEq/100 g) was calculated by Equation (7).
Acidity
Volume of NaOH Normality
=
× × 100
0 01.
(7)
2.11. Statistical analysis
Statistical analysis of the pharmacological activity of the syn-
thesized prodrugs on animals was evaluated using a one-
way analysis of variance (ANOVA). Unpaired t-test was applied
for expressing the significance and the experimental data are
expressed as mean ± SD.
3. Results and discussion
3.1. Physicochemical characterization
The product FLP-MET prodrug occurred as an offwhite-pale
yellow powder with a yield of 59%. TLC profile of FLP, MET and
FLP-MET in the eluent ethanol:water (70:30) gave Rf values of
0.82, 0.92 and 0.88 respectively. The results of Rf value, melting
point for synthesized FLP-MET prodrug were found to be dif-
ferent from parent drugs FLP, MET values indicating formation
of new compound and suggesting completion of reaction.
FLP-MET prodrug: Melting point: 114–117 °C. Molecular
weight: [M+] 457. IR (KBr disk): γ (cm−1) 3448.1, 3327.57 (N-H
stretching), 1681.62 (C=O stretching), 1259.29 (C—O stretch-
ing). 1H NMR (DMSO, 300 MHz): δ 1.54–1.59 (d, CH3); 7.28 (s, NH2);
6.912 to 7.58 (m, aromatic hydrogens); 3.7 to 4.32 (m, methine
and methylene protons); 3.86 (s, —OCH3). The ESI-MS shows
the molecular ion peak at m/z 458.1 (M+1). The results ob-
tained from IR spectra, NMR and mass spectra (Fig. 2)
demonstrate the characteristic of the anticipated structure of
the prodrug.
3.2. Solubility and partition coefficient studies
The solubility of synthesized prodrug studied in different sol-
vents is shown in Table 1. The FLP-MET prodrug was found to
be more soluble in methanol and ethanol followed by acetone,
chloroform, ether and very slightly soluble in water, thus in-
dicating a non-polar nature of the synthesized prodrug.
For oral administration of a drug, the drug having
octanol:water coefficient – log P > 2 is well absorbed, pro-
vided they have minimum solubility of 10 mg/ml. Results of
lipophilicity study are shown in Table 2. The results indi-
cated that the synthesized prodrug was relatively more
Table 1 – Solubility studies of FLP-MET prodrug.a
Sr. no. Solvent Solubility (mg/ml)
1 Water 0.4 ± 0.015
2 Ethanol 36 ± 0.158
3 Methanol 69 ± 0.070
4 Acetone 19 ± 0.292
5 Chloroform 14 ± 0.070
6 Ether 6 ± 0.114
a Data expressed as mean ± SD (n = 5).
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lipophilic as compared to parent drugs, thus making the syn-
thesized prodrug suitable for oral administration. Partition
coefficient results also suggested that mutual prodrug could
cross the biological barrier to reach the systemic circulation.
3.3. Protein binding studies
Results obtained from protein binding studies indicated the
low protein binding nature of the synthesized prodrug FLP-MET
Fig. 2 – NMR and mass spectra of the FLP-MET prodrug.
Table 2 – Lipophilicity studies of FLP-MET prodrug.a
Sr. No. System used Partition coefficient
1 Octanol:Water 5.13 ± 0.148
2 Octanol:Water (pH 1.2) 1.32 ± 0.018
3 Octanol:Water (pH 7.4) 4.72 ± 0.027
a Data expressed as mean ± SD (n = 5).
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as compared to the pure drugs flurbiprofen and methocarbamol
(Table 3). It was seen that the % concentration of unbound FLP-
MET prodrug was 44.82% as compared to 22.62% of unbound
flurbiprofen and 19.56% of unbound methocarbamol. As a result,
more amount of free prodrug would be available at the target
site and thus will be effective at low doses.
3.4. Hydrolysis study of mutual prodrug
Hydrolysis study was carried out to investigate the effect of
certain factors like temperature, pH, SGF, SIF and plasma and
enzymes on synthesized mutual prodrug. An HPLC method was
developed to separate selectively the two drugs and the mutual
prodrug. Fig. 3 shows the HPLC chromatogram used for the
quantification of un-hydrolyzed FLP-MET prodrug. Data related
to the method development have not been presented. The ki-
netics of ester hydrolysis of the synthesized prodrug was studied
in different buffer solutions having pH 3, 4, 5, 7.4, and in SGF
(pH 1.2) and SIF (pH 6.5). Also, the effect of activated esterase
enzymes present in plasma was investigated to mimic the ap-
propriate clinical range. Results presented in Table 4 indicated
that a minimal amount of the prodrug hydrolyzed at gastric
pH 3, 4, 5 and in SGF, SIF and also at the physiological pH 7.4.
However the prodrug rapidly hydrolyzed in plasma, suggest-
ing the activity of esterase enzyme present in the plasma acting
on the prodrug.
The reaction kinetics for degradation of the ester prodrug
to its parent compounds was of first order and a quantitative
conversion to FLP and MET was observed by HPLC analysis.
From Table 5, it is clear that the t1/2 of the mutual prodrug of
FLP-MET at various pH from 3 to 7.4 simulated gastric fluid and
simulated intestinal fluid was found to be in the range of 8.4
to 13.54 h. However the t1/2 of FLP-MET prodrug in plasma was
found to be 4.42 min with a k-value of 1.566 × 10−1, which
Table 3 – Protein binding studies of FLP-MET prodrug at
various time intervals.a
Time
in
hours
% Flurbiprofen
unbound
% Methocarbamol
unbound
% FLP-MET
prodrug
unbound
1 12.21 ± 0.026 9.66 ± 0.811 29.57 ± 3.900
2 16.39 ± 0.05 14.60 ± 0.7 36.04 ± 2.196
3 22.62 ± 0.03 19.56 ± 0.737 44.82 ± 1.843
a Data expressed as mean ± SD (n = 3).
Fig. 3 – HPLC chromatogram indicating separation of FLP-MET prodrug from parent drugs.
Table 4 – Hydrolysis study of FLP-MET prodrug in different conditions.a
Time
(min)
% FLP-MET prodrug remaining at different pH Time
(min)
% FLP-MET prodrug
remaining in plasma
pH 3 pH 4 pH 5 pH 7.4 SIF SGF
15 96.44 ± 0.609 97.09 ± 0.247 95.68 ± 1.414 97.29 ± 0.790 89.49 ± 0.714 88.63 ± 0.943 1 91.39 ± 1.546
30 94.40 ± 1.855 95.96 ± 0.970 94.28 ± 1.023 96.59 ± 0.949 88.32 ± 0.909 87.43 ± 0.934 5 77.79 ± 0.832
60 91.64 ± 1.999 93.65 ± 1.404 92.35 ± 2.520 95.13 ± 1.005 86.82 ± 0.966 86.18 ± 1.039 10 55.40 ± 1.871
120 89.45 ± 1.474 89.92 ± 1.462 88.69 ± 2.324 94.55 ± 0.763 84.26 ± 0.821 82.60 ± 0.927 15 40.93 ± 0.955
180 87.83 ± 1.359 87.95 ± 1.204 86.19 ± 0.971 93.63 ± 0.697 82.15 ± 0.880 80.84 ± 0.830 20 33.73 ± 0.724
a Data expressed as mean ± SD (n = 3).
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strikingly indicated that the drug underwent hydrolysis in
presence of the esterases in the plasma. The data given in
Table 5 followed a first order kinetics for hydrolysis. The
prodrug did not show significant hydrolysis at pH 3, 4, 5, 7.4
and in SGF (pH 1.2) and SIF (pH 6.5), suggesting that the
prodrug is relatively stable at this pH. The stability to pH hy-
drolysis implied that the compound can pass un-hydrolyzed
through the stomach on oral administration and can be hy-
drolyzed by enzymes present in plasma releasing the parent
compounds.
3.5. Biological activities
The anti-inflammatory activity was calculated as percentage
inhibition of edema. The % inhibition of edema for mutual
prodrug was comparable with parent NSAID (flurbiprofen). Fig. 4
demonstrates the results of anti-inflammatory activity. A
maximum anti-inflammatory activity of mutual prodrug (FLP-
MET) was observed 83.75% at 4 h and 92.51% at 5 h. Statistical
significance testing using unpaired t-test showed that the anti-
inflammatory activity of FLP-MET prodrug was comparable to
that of flurbiprofen (P < 0.05).
From the comparative study between flurbiprofen and the
mutual prodrug, it is observed that the percentage of protec-
tion by FLP-MET prodrug against pain (writhing) induced by
injection of irritant is comparable with the parent drug
flurbiprofen. The results given in Table 6 show the compara-
tive analgesic activity of FLP and FLP-MET prodrug.
Skeletal muscle relaxant activity was screened after
intra-peritoneal dosing to the mice with control, test and
standard drug. The results showed that skeletal muscle
relaxant activity of prodrug was comparable to that of me-
thocarbamol. Results of skeletal muscle relaxant activity are
shown in Table 7.
Ulcerogenic activity of the synthesized prodrug was screened
after treating the mice with equimolar quantity of flurbiprofen
and synthesized prodrug for 2 d. Ulcerogenic experiments in
mice revealed that administration of flurbiprofen over a period
of 2 d resulted in a high incidence of gastric mucosa lesions
shown by the ulcerative index which was found to be 26.9,
whereas the results of the ulcerogenic activity of synthe-
sized prodrug show that replacement of a carboxylic residue
by an ester group could remarkably reduce the gastric ulcer-
ation (Table 7). At molecular equivalent quantity, the number
of ulcers in gastric mucosa was markedly smaller in animals
treated with the prodrug FLP-MET and ulcerative index was
found to be 3.2.
The stomach specimen of the treated experimental animals
under the microscope (biopsy) provided a precise method for
investigation of the ulcerogenic potential of the NSAID and syn-
thesized mutual prodrug. Fig. 5 shows microscopic structures
of the stomach tissues under the same magnification. As seen
from the figure, the group treated with the flurbiprofen showed
complete damage of mucous layer besides submucosal ulcer-
ation. These effects were not observed with the group treated
with control. In the case of the prodrug, these effects are
minimal. This observation affords good evidence for the safety
of the suggested oral delivery system of prodrug compared with
Table 5 – k and t1/2 values at different conditions for FLP-
MET prodrug.
Conditions k (/h) t1/2
pH 3 7.686 × 10−2 9.01 hr
pH 4 8.252 × 10−2 8.4 hr
pH 5 7.548 × 10−2 9.18 hr
pH 7.4 5.118 × 10−2 13.54 hr
Simulated gastric fluid (SGF) 5.344 × 10−2 12.97 hr
Simulated intestinal fluid (SIF) 5.589 × 10−2 12.39 hr
Plasma 1.566 × 10−1 4.42 min
Fig. 4 – Comparison of anti-inflammatory activity of FLP
and FLP-MET prodrug.
Table 6 – Percent protection in acetic acid induced
writhing by flurbiprofen and FLP-MET prodrug.
Treatment Average number of
writhinga
% protectiona
Control 16.66 ± 2.516 –
Flurbiprofen 5.6 ± 0.577 65.98 ± 3.464
FLP-MET 7.3 ± 0.527 55.97 ± 3.125
a Data expressed as mean ± SD (n = 3).
Table 7 – Muscle relaxant activity, ulcerogenic activity
and total acid content activity of flurbiprofen,
methocarbamol and FLP-MET prodrug in mice.a
Treatment Muscle
relaxant
activity
Ulcerogenic
activity
Total acid
content
activity
% Decrease
in time
Ulcer
index
Total acidity
(mEq/100gm)
Control 7.446 ± 3.840 1.56 ± 0.30 24.66 ± 2.51
Flurbiprofen NA 26.9 ± 2.50 58.33 ± 4.04
Methocarbamol 88.96 ± 1.8569 NA NA
FLP-MET 84.90 ± 1.6781 3.2 ± 0.26 43.66 ± 3.05
a Data expressed as mean ± SD (n = 3).
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the traditional use of the parent drug. Table 6 shows a
comparison of ulcer index after administering test com-
pound and standard drug.
The values of total acid content in the case of the mice
treated with flurbiprofen and the synthesized prodrug were de-
termined. Results of total acid content activity are given in
Table 7. The amount of acid secreted was found to be less in
the case of the synthesized prodrug as compared to their parent
NSAID flurbiprofen, which indicates that the synthesized com-
pound possesses less tendency to produce gastric acid as
compared to standard drug flurbiprofen, hence minimizing GI
side effects.
4. Conclusion
A mutual prodrug was synthesized from the parent drugs
flurbiprofen and methocarbamol. Absorption bands obtained
in IR and NMR spectrum confirmed the formation of ester
linkage between flurbiprofen and methocarbamol. The chemi-
cal and enzymatic hydrolysis studies of ester prodrug at
different pH and in simulated gastric fluid and in simulated
intestinal fluid did not show significant hydrolysis, suggest-
ing that that the prodrug was quite stable at these pH values.
However, the hydrolysis of prodrug in plasma indicates rapid
hydrolysis, suggesting the activity of esterase enzyme present
in the stomach acting on the prodrug showing the fulfill-
ment of the prodrug design. Protein binding studies indicated
the low protein binding nature of the synthesized prodrug as
compared to the parent drugs, which translates to an in-
crease in bioavailability of the prodrug and thus requirement
of lower doses. In case of biological activities anti-inflammatory,
analgesic and skeletal muscle relaxant activity, the activity of
the synthesized prodrug was found to be comparable with stan-
dard drugs. Ulcerogenic activity and total acid content activity
studies showed that the ulcerogenic lesions and gastric acid
produced by prodrug were less when compared to the parent
drug flurbiprofen, thus indicating that the prodrug formed has
less ulceration potential and gastrointestinal side effects as
compared to the parent drugs.
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